Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 621.40M P/E - EPS this Y -5.60% Ern Qtrly Grth -
Income -75.45M Forward P/E -8.07 EPS next Y -22.20% 50D Avg Chg -4.00%
Sales - PEG 0.55 EPS past 5Y - 200D Avg Chg 24.00%
Dividend N/A Price/Book 2.50 EPS next 5Y -21.10% 52W High Chg -26.00%
Recommedations 1.70 Quick Ratio 44.05 Shares Outstanding 52.54M 52W Low Chg 165.00%
Insider Own 5.33% ROA -16.66% Shares Float 16.03M Beta 1.03
Inst Own 99.13% ROE -23.63% Shares Shorted/Prior 2.05M/3.27M Price 14.60
Gross Margin - Profit Margin - Avg. Volume 76,406 Target Price 25.20
Oper. Margin - Earnings Date Aug 8 Volume 42,123 Change 1.39%
About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Tyra Biosciences, Inc. News
06/07/24 Tyra Biosciences (TYRA) Upgraded to Buy: What Does It Mean for the Stock?
06/07/24 Wall Street Analysts See a 27.27% Upside in Tyra Biosciences (TYRA): Can the Stock Really Move This High?
05/23/24 Tyra Biosciences to Present at Upcoming Investor Conferences
05/13/24 Tyra Biosciences (NASDAQ:TYRA) Is In A Good Position To Deliver On Growth Plans
05/09/24 Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
05/07/24 Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors
08:01 PM Tyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline Progress
03:05 PM Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
03/05/24 Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 Shares
03/01/24 Insider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 Shares
02/07/24 Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
02/07/24 President and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA)
02/02/24 Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
02/01/24 Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
12/29/23 16 Most Promising Long-Term Stocks According to Analysts
12/22/23 Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300
11/08/23 Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference
11/07/23 Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
09/21/23 Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings
09/17/23 We Think Tyra Biosciences (NASDAQ:TYRA) Can Afford To Drive Business Growth
TYRA Chatroom

User Image Stocksrunner Posted - 1 week ago

$TYRA has been on a roll, with a recent 11.5% gain. With analysts forecasting further upside, it’s a stock to keep an eye on for potential breakout opportunities.

User Image DonCorleone77 Posted - 1 month ago

$TYRA Tyra Biosciences price target raised to $28 from $25 at Oppenheimer Oppenheimer raised the firm's price target on Tyra Biosciences to $28 from $25 and keeps an Outperform rating on the shares following the company's Q1 earnings results. The firm noted that it has recently noticed an uptick in investor interest in the story, which it feels "isn't surprising as we approach initial data from SURF301 later this year."

User Image Thestocktraderhubzee Posted - 1 month ago

$TYRA HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $23 Price Target

User Image DonCorleone77 Posted - 1 month ago

$TYRA Tyra Biosciences reports Q1 EPS (35c), consensus (45c) "During the first quarter of 2024, we focused on execution across our pipeline including delivering on our near-term milestones for TYRA-300 in both achondroplasia and oncology," said Todd Harris, CEO of TYRA. "In oncology, the TYRA-300 clinical profile continues to mature in SURF301, and our clinical team is focused on Part B dose expansion to evaluate multiple dosing regimens of TYRA-300. We believe this work will support future Phase 2 studies in NMIBC and metastatic urothelial carcinoma, where we see tremendous opportunity for an oral FGFR3-selective inhibitor. In achondroplasia, we remain on track to submit our IND in the second half of 2024 to support our planned Phase 2 study."

User Image Stock_Titan Posted - 1 month ago

$TYRA Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-first-quarter-2024-financial-results-and-0urr5hljmef3.html

User Image Doozio Posted - 1 month ago

$TYRA wen 🧠⏰ if no faatch 💣?

User Image DailyStocksPicks Posted - 03/24/24

Acelyrin ($SLRN): Acelyrin’s stock is perceived as oversold due to the divergence between its clinical advancements, institutional support, and analysts' optimistic forecasts versus its recent stock performance. Despite facing downward pressure, the company’s engagement in critical clinical trials and backing from notable institutional investors suggest an underappreciation of its value and potential, especially when considering its innovative pipeline in addressing unmet medical needs. $TYRA, $ZYME, $PHVS, $WVE For More Details: https://youtu.be/yeL_bMBSsNQ

User Image erevnon Posted - 03/21/24

Wedbush reiterates Tyra Biosciences $TYRA at Outperform and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image fda_tracker Posted - 03/20/24

$TYRA New PDUFA Date 2024-04-23 Tyra Biosciences, Inc. Link:https://www.sec.gov/Archives/edgar/data/0001863127/000095017024033461/tyra-20231231.htm Calendar:http://www.fdatracker.com/fda-calendar/

User Image erevnon Posted - 03/20/24

HC Wainwright & Co. reiterates Tyra Biosciences $TYRA at Buy and raises the price target from $19 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image DonCorleone77 Posted - 3 months ago

$TYRA Tyra Biosciences files to sell 15.37M shares of common stock for holders

User Image DonCorleone77 Posted - 3 months ago

$TYRA Tyra Biosciences reports Q4 EPS (53c), consensus (48c) As of December 31, 2023, TYRA had cash, cash equivalents, and marketable securities of $203.5M. "2023 was an outstanding year for TYRA and we are pleased to have positive momentum at the start of 2024," said Todd Harris, CEO of TYRA. "We have strong conviction in our pipeline and believe our lead program TYRA-300 has the potential to become a best-in-class agent for multiple high-value indications. TYRA-300 remains our top priority and we are focused on submitting our Phase 2 IND for achondroplasia, while optimizing dose in SURF301 in preparation for Phase 2 studies in NMIBC and metastatic urothelial carcinoma."

User Image Stock_Titan Posted - 3 months ago

$TYRA Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights https://www.stocktitan.net/news/TYRA/tyra-biosciences-reports-fourth-quarter-and-full-year-2023-financial-3736evb31ve4.html

User Image insiderbuyingselling Posted - 3 months ago

$TYRA new insider selling: 200 shares. http://insiderbuyingselling.com/?t=TYRA

User Image Stock_Titan Posted - 02/27/24

$TYRA Tyra Biosciences to Present at Upcoming Investor Conferences https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-upcoming-investor-ymxalybdlpqb.html

User Image insiderbuyingselling Posted - 4 months ago

$TYRA new insider selling: 1501 shares. http://insiderbuyingselling.com/?t=TYRA

User Image StockScanners Posted - 4 months ago

$TYRA We reached 20 lets go!, testing resistance, lets see what this does into next week

User Image insiderbuyingselling Posted - 4 months ago

$TYRA new insider selling: 9587 shares. http://insiderbuyingselling.com/?t=TYRA

User Image ArcherGreenaway Posted - 4 months ago

$EVER $TYRA $SSP Analyst price target for today() https://live-alerts-stock-trades.daytrading.network

User Image Stock_Titan Posted - 4 months ago

$TYRA Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference https://www.stocktitan.net/news/TYRA/tyra-biosciences-to-present-at-oppenheimer-s-34th-annual-healthcare-9ea44vd4hkyv.html

User Image TickerDD_com Posted - 4 months ago

From 12/22/2023, looking back across 22 Month-Ends for TYRA, Percentage Change of Average Monthly Price had More Positives (64%) while Percentage Change of Average Monthly Volume had All Positives (100%) $TYRA #TYRA #TYRAStock #TickerDD #TYRAPrice https://www.youtube.com/watch?v=RYkrz2UwRRQ

User Image RealisticPerson Posted - 4 months ago

$NYCB diff sector but this one is up big on pp @ $13 and ceo selling ~ pipeline is only at phase 1... potential short/put plays. Not sure how its holding up so well but check out $TYRA

User Image RealisticPerson Posted - 4 months ago

$TYRA wow so much confidence here....

User Image Noisy Posted - 4 months ago

$TYRA very resilient, ceo sells 100000 shares and the stock still goes up lol

User Image insiderbuyingselling Posted - 4 months ago

$TYRA new insider selling: 100000 shares. http://insiderbuyingselling.com/?t=TYRA

User Image Doozio Posted - 4 months ago

$TYRA chop chop huckleberries 🧠⏰

User Image StockScanners Posted - 4 months ago

$TYRA Reached 18.48, keep on watch

User Image RealisticPerson Posted - 4 months ago

$TYRA PP suppose to close today, there will be more shares in the market, will see more movement eventually

User Image wpotter40 Posted - 4 months ago

$TYRA this ticker scares me at this point haha. It just keeps climbing and has yet to really correct from its big day last week. The bid/ask spread has been nearly 70 cents at times and the volume is extremely low. One whale decides to sell while it’s this high and this thing comes back down several dollars.

User Image StockScanners Posted - 4 months ago

$TYRA Watch as long as this keeps hot above 16

Analyst Ratings
HC Wainwright & Co. Buy Jun 5, 24
Oppenheimer Outperform May 13, 24
Wedbush Outperform May 10, 24
HC Wainwright & Co. Buy May 10, 24
Wedbush Outperform Mar 21, 24
HC Wainwright & Co. Buy Mar 20, 24
Wedbush Outperform Dec 29, 23
HC Wainwright & Co. Buy Dec 26, 23
HC Wainwright & Co. Buy Nov 8, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Feb 02 Sell 17.15 90,806 1,557,323 462,568 02/06/24
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Feb 02 Option 0.61 25,393 15,490 553,374 02/06/24
Harris Todd President and CEO President and CEO Feb 02 Sell 16.82 100,000 1,682,000 1,502,697 02/06/24
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 19 Sell 16.04 4,107 65,876 527,981 07/21/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 19 Option 0.61 4,107 2,505 531,881 07/21/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 13 Sell 16.08 2,400 38,592 527,981 07/17/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 13 Option 0.61 2,400 1,464 529,881 07/17/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 10 Option 0.61 1,903 1,161 528,182 07/12/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jul 10 Sell 16.09 1,903 30,619 527,981 07/12/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 29 Sell 16.7 40,365 674,096 527,981 07/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 29 Option 0.61 40,365 24,623 532,246 07/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 26 Sell 16.89 46,784 790,182 527,981 06/28/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 26 Option 0.61 46,784 28,538 541,505 06/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 22 Sell 17.16 24,190 415,100 1,601,276 06/26/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 16 Sell 17.23 75,810 1,306,206 1,625,466 06/21/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 13 Sell 16.07 20,700 332,649 1,701,276 06/15/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Jun 13 Option 2.25 20,700 46,575 1,714,049 06/15/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 13 Sell 16.2 18,340 297,108 527,981 06/15/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Jun 13 Option 0.61 18,340 11,187 540,573 06/15/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Apr 03 Sell 16.13 2,000 32,260 1,701,276 04/05/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Apr 03 Option 2.25 2,000 4,500 1,703,276 04/05/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 30 Sell 16.06 4,400 70,664 527,981 04/03/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 30 Option 0.61 4,400 2,684 529,981 04/03/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 29 Sell 16.08 4,327 69,578 1,701,276 03/31/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 29 Option 2.25 4,327 9,736 1,701,776 03/31/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 27 Sell 16.07 13,581 218,247 527,981 03/29/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 27 Option 0.61 13,581 8,284 530,168 03/29/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 24 Sell 16 5,912 94,592 1,701,276 03/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 24 Option 2.25 5,912 13,302 1,704,055 03/28/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 21 Sell 16 19,236 307,776 1,701,276 03/23/23
Harris Todd Chief Executive Offi.. Chief Executive Officer Mar 21 Option 2.25 19,236 43,281 1,704,076 03/23/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 21 Sell 16 22,727 363,632 527,981 03/23/23
Bensen Daniel Chief Operating Offi.. Chief Operating Officer Mar 21 Option 0.61 22,727 13,863 532,808 03/23/23
MVA Investors, LLC 10% Owner 10% Owner Feb 09 Sell 13.25 265,568 3,518,776 22,527 02/13/23